Influence of single and multiple doses of oral ranitidine on the gastric transit of an indigestible capsule in humans.
The effect of single and multiple doses of ranitidine on the gastric residence time of an indigestible pH-sensitive radiotelemetric device, the Heidelberg capsule, was evaluated in 12 healthy men (mean age, 29 +/- 8 years) in a placebo-controlled, randomized, crossover study. Each subject received 150 mg ranitidine or placebo orally 2 hours before administration of the Heidelberg capsule. A 500 kcal standardized breakfast was served 1/2 hour before the capsule was administered. Gastric pH was monitored at 15-minute intervals, until pyloric passage (pH increase greater than or equal to 3 U) of the Heidelberg capsule was observed. Blood samples (n = 12) were collected 0 to 8 hours after administration of drug or placebo. The subjects continued to receive ranitidine or placebo b.i.d. for 7 days and returned on day 8 for a similar evaluation. After a 1-week washout period, the subjects received the alternative treatment. The mean (+/- SD) gastric residence time of the Heidelberg capsule was significantly decreased after both single and multiple doses of ranitidine compared to placebo (3.1 +/- 0.9 versus 3.8 +/- 1.1 hours, p less than 0.02; and 2.9 +/- 0.74 versus 3.9 +/- 0.9 hours, p less than 0.005, n = 9). Gastric residence time was not determined in three subjects who showed unusually slow gastrointestinal motility after both placebo and ranitidine. Mean AUC(0-8 hr) and AUC(0-infinity) were significantly increased, whereas Cmax, tmax, and t1/2 remained unchanged after 7 days of ranitidine b.i.d. treatment. No ranitidine double-peak profile or linear pharmacokinetic-pharmacodynamic relationship was identified.(ABSTRACT TRUNCATED AT 250 WORDS)
Mojaverian
P
P
Department of Clinical Pharmacology, Jefferson Medical College of Thomas Jefferson University, Philadelphia.
Vlasses
P H
PH
Parker
S
S
Warner
C
C
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D002214:Capsules; D004311:Double-Blind Method; D005746:Gastric Emptying / Q000187:drug effects*; D005772:Gastrointestinal Transit / Q000187:drug effects*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D011899:Ranitidine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D013270:Stomach / Q000187:drug effects
D002214:Capsules; D011899:Ranitidine